Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ETS2
REST API REST API
Homo sapiens
ETS2 is differentially expressed in 355 experiments: 136 organism parts: lung, bone marrow, ... (134 more);, 217 disease states: normal, control, ... (215 more);, 123 cell types 442 cell lines 63 compound treatments and 76 other conditions.
Orthologs Ets2 (Rattus norvegicus)   ETS2 (Gallus gallus)   ets2 (Danio rerio)   F6Q0N1_CIOIN (Ciona intestinalis)   Q2QCT6_BOVIN (Bos taurus)   Ets2 (Mus musculus)   pnt (Drosophila melanogaster)   ets2 (Xenopus laevis)   ETS2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, positive regulation of transcription, DNA-dependent, glucocorticoid receptor binding, skeletal system development, sequence-specific DNA binding transcription factor activity
InterPro Term Ets, Transforming_factor_C-ets, Pointed_dom
UniProt Accession C9JAG2, P15036
Search EB-eye ENSG00000157557
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-2549, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
SNU5
2
E-GEOD-15460, E-MTAB-37
AGS
2
E-GEOD-15460, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
436 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (63 experiments)

Factor Value U/D Experiments
2
2
E-TABM-145, E-TABM-130
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
pro B cell
1
E-MEXP-1403
basal cell
1
E-GEOD-3998
117 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (71 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MTAB-62, E-GEOD-96, E-MEXP-2034, E-MEXP-1327
colon carcinoma
3
E-GEOD-3726, E-MTAB-37, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-62
211 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-1417, E-GEOD-5542, E-GEOD-5741, ... (40 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
lipopolysaccharide
2
E-TABM-868, E-GEOD-3720
nebivolol
1
E-GEOD-3356
5-fluorouridine
1
1
E-GEOD-995
Infergen
1
E-GEOD-5542
filtered air
1
E-TABM-127
57 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-MEXP-480, E-MTAB-69, ... (10 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-6432, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MEXP-1956, E-MEXP-2069, E-GEOD-1926, E-GEOD-16363, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Light
studied in E-GEOD-1725

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-595, E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-4525, E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, ... (9 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19136, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-6532

Processing time: 0.312 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM